The Evolution and Challenges of Nuclear Medicine: Insights from Germany

Abstract

This article provides an overview of the current state of nuclear medicine in Germany, one of the leading countries in this field in Europe, with a particular focus on the clinical framework of the Department of Nuclear Medicine at the University of Wuerzburg. In the diagnostic domain, the clinical application of molecular imaging, especially positron emission tomography (PET), is introduced, while in the therapeutic domain, the current status and future perspectives of targeted radionuclide therapy (TRT) directed at prostate-specific membrane antigen (PSMA) are discussed. Furthermore, recent years have seen growing interest from pharmaceutical and biotech companies in the nuclear medicine field, leading to accelerated mergers, acquisitions, and collaborations involving radiopharmaceutical companies. Additionally, Germany’s 2024 amendment to its Medical Research Act has improved the environment for conducting clinical research, establishing a regulatory framework that facilitates the clinical application of new radiopharmaceuticals. This article discusses these industrial trends and regulatory changes, along with the current status and future challenges of nuclear medicine as a fusion of diagnostics and therapy.